{
  "story_id": "12d1ccfcab922a19d1ea16253cdc842c",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-01T22:30:01.000Z",
  "content_hash": "d28fc5fe37b3d7c7f62a2e99ccfc765eae3cf7ba6000b26434ccbb8be25ce53e",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Study Identifies High-Risk Groups for SGLT2 Inhibitor-Induced Ketoacidosis",
    "dek": "New study identifies specific patient profiles at increased risk of ketoacidosis while taking SGLT2 inhibitors.",
    "prose": "A study led by researchers at Karolinska Institutet analyzed national health registry data from Sweden, Denmark, and Norway involving more than 280,000 patients with type 2 diabetes treated with SGLT2 inhibitors. [^1]\n\nPatients with type 2 diabetes who have high blood glucose levels, low body weight, or a history of ketoacidosis are at increased risk of developing ketoacidosis when treated with SGLT2 inhibitors. [^2]\n\nInfection was identified as the most common triggering or co-occurring event in cases of ketoacidosis among patients taking SGLT2 inhibitors. [^3]\n\nThe study showed that the risk of ketoacidosis remains elevated throughout the entire course of treatment, not just during the initial stages. [^4]\n\nArtificial intelligence can now analyze millions of chemical compounds and identify therapeutic molecules, reducing drug discovery times that historically required years and billions of dollars. [^5]\n\nCardiovascular diseases remain the leading cause of death worldwide, with over 20.5 million deaths per year, according to the World Heart Federation. [^6]\n\nThe author argues that the pharmaceutical industry is solving the wrong problem by focusing on diagnosis and treatment rather than prevention. [^7]\n\nThe author proposes that the next step is to build systems capable of continuous patient accompaniment using wearables, remote monitoring, and AI to intervene when habits are forming. [^8]",
    "cited": "[{\"statement\":\"A study led by researchers at Karolinska Institutet analyzed national health registry data from Sweden, Denmark, and Norway involving more than 280,000 patients with type 2 diabetes treated with SGLT2 inhibitors.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T22:30:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"Patients with type 2 diabetes who have high blood glucose levels, low body weight, or a history of ketoacidosis are at increased risk of developing ketoacidosis when treated with SGLT2 inhibitors.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T22:30:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"Infection was identified as the most common triggering or co-occurring event in cases of ketoacidosis among patients taking SGLT2 inhibitors.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T22:30:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"The study showed that the risk of ketoacidosis remains elevated throughout the entire course of treatment, not just during the initial stages.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T22:30:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"Artificial intelligence can now analyze millions of chemical compounds and identify therapeutic molecules, reducing drug discovery times that historically required years and billions of dollars.\",\"source\":\"El Financiero\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:31:25.000Z\",\"publisher_count\":1,\"sources\":[\"El Financiero\"]},{\"statement\":\"Cardiovascular diseases remain the leading cause of death worldwide, with over 20.5 million deaths per year, according to the World Heart Federation.\",\"source\":\"El Financiero\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:31:25.000Z\",\"publisher_count\":1,\"sources\":[\"El Financiero\"]},{\"statement\":\"The author argues that the pharmaceutical industry is solving the wrong problem by focusing on diagnosis and treatment rather than prevention.\",\"source\":\"El Financiero\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:31:25.000Z\",\"publisher_count\":1,\"sources\":[\"El Financiero\"]},{\"statement\":\"The author proposes that the next step is to build systems capable of continuous patient accompaniment using wearables, remote monitoring, and AI to intervene when habits are forming.\",\"source\":\"El Financiero\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:31:25.000Z\",\"publisher_count\":1,\"sources\":[\"El Financiero\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "72c20a72f99285fedaab589dbe5754d1",
      "thread_id": "4089d7d551f7eade410e4c2f935b3a46",
      "thread_label": "The Lancet Diabetes & Endocrinology",
      "novelty": "UPDATE",
      "content_hash": "21f10cf626aceda427cd34adf8e7fa1e3b9f77e1669d57a96985a36c183ed8f1",
      "last_published_at": "2026-09-01T22:30:01.000Z",
      "read_receipt": {
        "slice_hash": "dbe6cdac0c4b0fa348ae48b95036c17d7ce8ba5fde181b7c1a522f7ca1449694",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDFUMjI6MjE6MDkuMDAwMDAwWiIsImlkIjoiYzRkMTQ4MTI1YmM0NzI3ZGEzZGQyOGE4ZWExMzc1ODEiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDFUMjM6MDI6MjQuMDAwMDAwWiIsImlkIjoiODg0ODhiM2E1N2RmZGFmNjI4NGNlNmJjOTYxNGVkOWIiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12017721,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "Ax-YyrM52TSSNN8NGV19MpGcpC9N7PRxGF3XbJfPaKkR3fgI5xeA4XZARjTDujAnlqd35hCrExVtofOQfBwmCA",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-02T22:21:31.576Z"
  },
  "cited_facts": [
    {
      "statement": "A study led by researchers at Karolinska Institutet analyzed national health registry data from Sweden, Denmark, and Norway involving more than 280,000 patients with type 2 diabetes treated with SGLT2 inhibitors.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T22:30:01.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "Patients with type 2 diabetes who have high blood glucose levels, low body weight, or a history of ketoacidosis are at increased risk of developing ketoacidosis when treated with SGLT2 inhibitors.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T22:30:01.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "Infection was identified as the most common triggering or co-occurring event in cases of ketoacidosis among patients taking SGLT2 inhibitors.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T22:30:01.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "The study showed that the risk of ketoacidosis remains elevated throughout the entire course of treatment, not just during the initial stages.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T22:30:01.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "Artificial intelligence can now analyze millions of chemical compounds and identify therapeutic molecules, reducing drug discovery times that historically required years and billions of dollars.",
      "source": "El Financiero",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:31:25.000Z",
      "publisher_count": 1,
      "sources": [
        "El Financiero"
      ]
    },
    {
      "statement": "Cardiovascular diseases remain the leading cause of death worldwide, with over 20.5 million deaths per year, according to the World Heart Federation.",
      "source": "El Financiero",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:31:25.000Z",
      "publisher_count": 1,
      "sources": [
        "El Financiero"
      ]
    },
    {
      "statement": "The author argues that the pharmaceutical industry is solving the wrong problem by focusing on diagnosis and treatment rather than prevention.",
      "source": "El Financiero",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:31:25.000Z",
      "publisher_count": 1,
      "sources": [
        "El Financiero"
      ]
    },
    {
      "statement": "The author proposes that the next step is to build systems capable of continuous patient accompaniment using wearables, remote monitoring, and AI to intervene when habits are forming.",
      "source": "El Financiero",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:31:25.000Z",
      "publisher_count": 1,
      "sources": [
        "El Financiero"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}